AB Technology announces data from development program of masitinib in GIST AB Technology SA.

After 18 months, 82 percent [59 percent; 93 percent] of sufferers treated with masitinib were still alive, versus 33 percent [8 percent; 62 percent] for patients treated with sunitinib. Masitinib was well tolerated, with 17 percent of patients reporting non-hematological quality 3 related adverse events, in comparison with 62 percent of sufferers in the sunitinib treatment-arm. No patients receiving masitinib reported any related serious adverse events weighed against 19 percent of individuals in the sunitinib treatment-arm. Related StoriesStudy reveals system behind protein-related diseasesNew Global International and Energy Sustainability Group agree to manufacture, distribute MoringaUP Protein BarsResearchers recognize tumor suppressor genes that drive subset of melanomas A phase III research provides been initiated in this indication based on these total results, with recruitment of the 1st patient announced on 15th May 2012.With the 30-month project completed and scientific trials of the prototype effectively concluded by Kaunas Medical University’s Institute of Cardiology, the Lithuania Academy of Physical Education and the Research Institute of Cardiology at the University of Latvia, the next steps are to satisfy the EU’s strict compliance requirements for medical gadgets and source a firm to produce and distribute the system. If successful, the 1st commercial HEART GUARD gadgets could be on the market and conserving lives by the end of 2008 or early 2009.

AP: Poll shows support for health rules drops with budget woes The Associated Press: Poll Displays Health Care Law Support Dips On Budget Woes Amid a budget debate that will affect medical care of virtually every family, a new poll finds support for President Barack Obama’s overhaul at its lowest level since passage last year.